Amgen Reports Second Quarter 2018 Financial Results
THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2018. Key results include: Total revenues increased 4 percent versus the second quarter of 2017 to $6.1 billion. Product sales grew 2 percent globally. New and recently launched products including Repatha® (evolocumab), KYPROLIS® (carfilzomib), Prolia® (denosumab) and XGEVA® (denosumab), showed double-digit growth. GAAP earnings per share (EPS) increased 20 percent to $3.48 driven by higher product sales, a lower tax rate and lower weighted-average shares outstanding. ...
Source: Amgen News Release - July 26, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Webcast of 2018 Second Quarter Financial Results
THOUSAND OAKS, Calif., July 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2018 financial results on Thursday, July 26, 2018, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investo...
Source: Amgen News Release - July 24, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Cedars-Sinai Partner For Improved Healthcare Quality
First Amgen Collaboration With Academic Medical Center Focused on Research, Health Service Redesign and Outcomes-Based Care THOUSAND OAKS, Calif. and LOS ANGELES, July 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Cedars-Sinai Medical Center today announced a partnership to help support the improvement of healthcare quality in the treatment of multiple therapeutic areas that could include oncology, cardiovascular disease, osteoporosis and migraine. The organizations intend to jointly undertake research projects in one or more of these therapeutic areas. They also plan to focus on projects that could achieve better...
Source: Amgen News Release - July 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP ™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma
Discussion With Doctor to Create Individualized Treatment Plan Don Baylor Jr., Son of Former MLB Most Valuable Player Don Baylor, Honors Late Father's Legacy by Raising Multiple Myeloma Awareness Through Campaign Amgen to Recognize Local Multiple Myeloma Communities at Select MLB Games in 2018 THOUSAND OAKS, Calif., July 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of Myeloma MVPTM, a national campaign to help those affected by multiple myeloma create their Most Valuable Plan, an individualized approach for managing their disease. Multiple myeloma is an incurable blood ... (Source: Amgen News Release)
Source: Amgen News Release - July 18, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY ™ (romosozumab) To The US FDA
BLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 Patients THOUSAND OAKS, Calif. and BRUSSELS, July 12, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™* (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY increases bone formation and reduces bone resorption simultaneously to increase bone mineral density (BMD) and reduce the risk of fracture. "...
Source: Amgen News Release - July 13, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen and MBC Biolabs Announce Winners of the Amgen Golden Ticket
Two Biotherapeutic Companies Receive Lab Space and Other Benefits at Bay Area Life Sciences IncubatorTHOUSAND OAKS, Calif. and SAN FRANCISCO (June 29, 2018) - Amgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) announced today that Delve Therapeutics and Mitokinin have won the Amgen Golden Ticket at MBC BioLabs. Each company receives one year of lab bench space and access to core facilities at the MBC BioLabs life sciences incubator, as well as connections to Amgen’s scientific and business leaders to help advance its scientific programs. Amgen first sponsored MBC BioLabs in 2015 to assist high-potential and...
Source: Amgen News Release - June 29, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig ™ (erenumab-aooe) In Patients With Chronic And Episodic Migraine
Results From a One-Year Study of Efficacy and Safety of Aimovig in Chronic Migraine and Data From a Three-Year Analysis Assessing Safety and Tolerability of Aimovig in Episodic Migraine Will be Presented at the American Headache Society Annual Meeting Aimovig Showed Robust Efficacy in Patients With Chronic Migraine, With Reductions in Monthly Migraine Days Sustained Throughout the Study Established Safety Profile of Aimovig Reinforced With Chronic and Episodic Migraine Data THOUSAND OAKS, Calif., June 28, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the results of ...
Source: Amgen News Release - June 28, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Health And Benefits Consultant Piper Jordan Partner On First Migraine Project With Employers
$11 Billion is Estimated to be Lost by American Employers Each Year Due to Migraine Collaboration Underscores Amgen's Commitment to Reducing Migraine Stigma in the Workplace THOUSAND OAKS, Calif. and SAN DIEGO, June 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Piper Jordan, one of the nation's leading health and benefits consulting firms, today announced a unique partnership to help improve health and well-being in the workplace for people living with migraine. The collaboration aims to provide disease management resources to both the employee and employer through innovative educational programs, including we...
Source: Amgen News Release - June 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Novartis Highlight Findings From A Large Global Patient Survey Revealing That Worldwide Approximately 60 Percent Of Employed People With Migraine Missed, On Average, A Week Of Work In A Month
The My Migraine Voice Survey Involved More Than 11,000 People Globally, 10 Percent of Which Were From the U.S., and Highlights Urgent Need for Better Care for Benefit of Patients and Society In the U.S., Patients Reported Eighty Percent of Employers Knew About Their Migraine, but Only 21 Percent Offered Support Migraine is Estimated to Cost Up to $22 Billion in the U.S. Annually, Including Indirect Costs Such as Lost Productivity; Survey Finds 18 Percent of Worktime is Missed Due to Migraine in the U.S. THOUSAND OAKS, Calif., June 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced initial findings from ...
Source: Amgen News Release - June 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab
Study Evaluated Efficacy and Safety of ABP 710 Compared With Infliximab in Patients With Moderate-to-Severe Rheumatoid Arthritis Amgen to Seek Regulatory Approvals THOUSAND OAKS, Calif., June 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 710 compared with REMICADE® (infliximab) in patients with moderate-to-severe rheumatoid arthritis. The results confirm non-inferiority compared to infliximab but could not rule out superiority based on its primary efficacy endpoint, which compared the response difference meas...
Source: Amgen News Release - June 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New Data Show Amgen's Repatha ® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes
Data Presented at the 78th Scientific Sessions of the American Diabetes Association THOUSAND OAKS, Calif., June 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data that show Repatha® (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with Type 2 diabetes and hypercholesterolemia or mixed dyslipidemia, taking the maximum tolerated dose of moderate/high-intensity statin therapy. BANTING was a dedicated study evaluating the efficacy of Repatha (monthly dosing), in lowering LDL-C and improving other lipid ...
Source: Amgen News Release - June 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO ® (blinatumomab) Label
BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., June 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO® (blinatumomab) based on the overall survival (OS) data from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). "BLINCYTO is the first single agent immunotherapy to demonstrate superior overall survival benefit over standard...
Source: Amgen News Release - June 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS ® (carfilzomib) Label
KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months KYPROLIS is the First and Only Treatment to Demonstrate Overall Survival Benefits in Two Phase 3 Studies in Relapsed or Refractory Multiple Myeloma THOUSAND OAKS, Calif., June 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for KYPROLIS® (carfilzomi...
Source: Amgen News Release - June 11, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

European Commission Approves Prolia ® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Third Indication in Europe for Prolia for the Treatment of Patients at Increased Risk of Fractures THOUSAND OAKS, Calif., June 8, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication for Prolia® (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. The EC approval is based on the positive results of a Phase 3 study that evaluated the safety and efficacy of Prolia compared with risedronate in patients receiving glucocorticoid treatment.1 "We are pl...
Source: Amgen News Release - June 8, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference
THOUSAND OAKS, Calif., June 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 39th Annual Global Healthcare Conference at 9:30 a.m. PT on Tuesday, June 12, 2018, in Rancho Palos Verdes, Calif. Elliott M. Levy, M.D., senior vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. About Amgen Amgen is committed to unlocking the potentia...
Source: Amgen News Release - June 7, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news